U.S. Markets close in 31 mins

Intercept Pharmaceuticals Inc (ICPT) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Intercept Pharmaceuticals Inc (ICPT) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Intercept Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases with high unmet medical need. Intercept Pharmaceuticals Inc has a market cap of $3.16 billion; its shares were traded at around $106.69 with and P/S ratio of 17.79.


For the last quarter Intercept Pharmaceuticals Inc reported a revenue of $53.3 million, compared with the revenue of $37.69 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $179.8 million, an increase of 37.3% from last year. For the last five years Intercept Pharmaceuticals Inc had an average revenue growth rate of 202.1% a year.

The reported loss per diluted share was $10.86 for the year, compared with the loss per share of $13.63 in the previous year. The Intercept Pharmaceuticals Inc had an operating margin of -158.78%, compared with the operating margin of -256.28% a year before. The 10-year historical median operating margin of Intercept Pharmaceuticals Inc is -1613.31%. The profitability rank of the company is 5 (out of 10).

At the end of the fiscal year, Intercept Pharmaceuticals Inc has the cash and cash equivalents of $436.2 million, compared with $70.0 million in the previous year. The company had no long term debt, compared with $355.7 million in the previous year. Intercept Pharmaceuticals Inc has a financial strength rank of 4 (out of 10).

At the current stock price of $106.69, Intercept Pharmaceuticals Inc is traded at 95.8% discount to its historical median P/S valuation band of $2533.32. The P/S ratio of the stock is 17.79, while the historical median P/S ratio is 422.36. The stock gained 80.89% during the past 12 months.

Directors and Officers Recent Trades:

  • EVP, Research & Development Christian Weyer sold 333 shares of ICPT stock on 03/01/2019 at the average price of $103.16. The price of the stock has increased by 3.42% since.
  • Chief Medical Officer David Shapiro sold 2,000 shares of ICPT stock on 03/01/2019 at the average price of $103.16. The price of the stock has increased by 3.42% since.
  • Director Srinivas Akkaraju sold 23,438 shares of ICPT stock on 02/19/2019 at the average price of $128.78. The price of the stock has decreased by 17.15% since.
  • Chief Medical Officer David Shapiro sold 2,000 shares of ICPT stock on 02/15/2019 at the average price of $111.51. The price of the stock has decreased by 4.32% since.

For the complete 20-year historical financial data of ICPT, click here.

This article first appeared on GuruFocus.